Veracyte, Inc.

VCYT

Precision medicineHealthcare diagnosticsGenomic analysis

$41.44vs prev close▼-0.87(-2.06%)

$28.2552W Range$60.91

40% from low

-15.07 (-26.62%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

1 sells

Concentrated sells

1M net buy

-$1.1M

≈ -21K shares

Portfolio Weight

0.70%

1M -0.16%p

Holding ETFs

2 ETFs

ARKG · ARKK

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -7.7% · Market value -26.5% · Weight -0.16%p

Trade Intensity

Minor adjustment

Basis: weight -0.16%p decrease

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.28	SELL	ARKK	20,539	$55.65	$1.1M
26.07.08	SELL	ARKG	67,476	$56.12	$3.8M
26.07.07	SELL	ARKG	12,424	$56.16	$697.7K
26.07.01	SELL	ARKK	55,672	$59.85	$3.3M
26.06.30	SELL	ARKK	20,797	$58.73	$1.2M
26.06.29	SELL	ARKK	33,193	$60.19	$2.0M
26.06.15	SELL	ARKK	166,427	$49.15	$8.2M
26.06.12	SELL	ARKK	62,392	$47.33	$3.0M
26.06.11	SELL	ARKK	55,841	$47.42	$2.6M
26.06.10	SELL	ARKK	143,385	$48.17	$6.9M
26.06.04	SELL	ARKK	28,488	$49.94	$1.4M
26.06.03	SELL	ARKK	112,075	$48.69	$5.5M
26.05.11	SELL	ARKG	23,834	$39.70	$946.2K
26.05.07	SELL	ARKG	14,238	$40.76	$580.3K
26.04.08	SELL	ARKG	4,956	$32.67	$161.9K

07.28SELL

20,539

ARKKClose$55.65Est. total$1.1M

07.08SELL

67,476

ARKGClose$56.12Est. total$3.8M

07.07SELL

12,424

ARKGClose$56.16Est. total$697.7K

07.01SELL

55,672

ARKKClose$59.85Est. total$3.3M

06.30SELL

20,797

ARKKClose$58.73Est. total$1.2M

06.29SELL

33,193

ARKKClose$60.19Est. total$2.0M

06.15SELL

166,427

ARKKClose$49.15Est. total$8.2M

06.12SELL

62,392

ARKKClose$47.33Est. total$3.0M

06.11SELL

55,841

ARKKClose$47.42Est. total$2.6M

06.10SELL

143,385

ARKKClose$48.17Est. total$6.9M

06.04SELL

28,488

ARKKClose$49.94Est. total$1.4M

06.03SELL

112,075

ARKKClose$48.69Est. total$5.5M

05.11SELL

23,834

ARKGClose$39.70Est. total$946.2K

05.07SELL

14,238

ARKGClose$40.76Est. total$580.3K

04.08SELL

4,956

ARKGClose$32.67Est. total$161.9K

1 / 8

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

1,878,703

Portfolio Weight

0.7%

in ETF 2.38%

Est. Value

$87M

30D Net

-$5M

Ray DalioBridgewater Associates

New Buy

28,394

Portfolio Weight

Est. Value

$1M

Change

New position

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Analyst Targets

avg.

$57.82

vs Current ▲ +36.7% upside

Current$42.31

Low ~ High$44.00 ~ $70.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Piper Sandler

Overweight

$54.00

+27.63%

—

Maintain

2026-08-04

Stephens & Co.

Overweight

$55.00

+29.99%

—

Maintain

2026-08-04

Morgan Stanley

Underweight

$44.00

+3.99%

—

Maintain

2026-08-04

Canaccord Genuity

Hold

$50.00

+18.18%

—

Maintain

2026-08-03

Needham

Buy

$69.00

+63.08%

—

Maintain

2026-07-31

1 / 4

Avg Target

$57.82

vs Current ▲ +36.7% upside

Buy

12 analysts

Strong Buy 2Buy 8Hold 1Sell 1

Low $44.00

Current $42.31

High $70.00

Firm	Position	Target	Upside	Close	Action	Date
Piper Sandler	Overweight	$54.00	+27.63%	—	Maintain	26.08.04
Stephens & Co.	Overweight	$55.00	+29.99%	—	Maintain	26.08.04
Morgan Stanley	Underweight	$44.00	+3.99%	—	Maintain	26.08.04
Canaccord Genuity	Hold	$50.00	+18.18%	—	Maintain	26.08.03
Needham	Buy	$69.00	+63.08%	—	Maintain	26.07.31

1 / 4

Price Information

Previous Close$41.79

Open$42.18

Day Range$41.10 - $42.53

52-Week Range$28.25 - $60.91

1-Year Change43.18%

Trading Volume

Volume954,569

Avg Volume (3mo)1,335,400

Valuation

Market Cap3.4B

Book Value$17.28

Shares Outstanding80,390,731

Financials

Revenue (TTM)561.9M

Net Income114.5M

EPS$1.40

EBITDA113.5M

Profitability

P/E Ratio30.22

P/B Ratio2.45

Return on Equity (ROE)8.77%

Return on Assets (ROA)4.09%

Profit Margin20.37%

EV/EBITDA26.04

Beta1.94

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)40.80

Company Overview

Veracyte, Inc. is a global diagnostics company that provides genomic tests to help diagnose cancer. Their main products include genomic classifiers for thyroid, prostate, bladder, and lung cancers, as well as a breast cancer assay. Veracyte aims to improve patient care by offering precise diagnostic solutions.

P/B

2.45

Price-to-Book

ROE

8.8%

Low return

Beta

1.94

High volatility

RSI(14)

40.8

Neutral zone

AI-generated summary. Not investment advice.

Veracyte, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks